Form 4: Veracyte Executive Phillip G. Febbo Reports Acquisition of Restricted Stock Units

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., reports the acquisition of restricted stock units.

Summary

• On March 6, 2025, Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., acquired 24,160 shares of common stock.
• These shares were acquired as restricted stock units at a price of $0.
• Following the transaction, Febbo directly owns 106,700 shares of Veracyte common stock.
• The restricted stock units vest 25% on March 2, 2026, and then 1/16 per quarter thereafter, contingent upon continued employment.

Sentiment

Score: 7

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The vesting schedule is a positive sign for long-term commitment.

Positives

• The acquisition of restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued employment and contribution to the company's success.

Industry Context

This is a standard practice for publicly traded companies to incentivize and retain key personnel through equity compensation.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies, particularly in the biotech industry.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules are generally structured to align executive compensation with long-term company performance, similar to industry norms.

Stakeholder Impact

• The acquisition of restricted stock units by a key executive can be viewed positively by shareholders as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates